Alexandria Real Estate Equities, Inc 8-K, filed Oct 9, 2007
Alexandria Real Estate Equities, Inc. (ARE)
About this 8-K
Alexandria Real Estate Equities, Inc filed this 8-K on October 9, 2007, reporting on events of October 4, 2007.
Items reported
- Item 8.01: Other events
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 4, 2007
ALEXANDRIA REAL ESTATE EQUITIES, INC.
(Exact name of registrant as specified in its charter)
|
Maryland |
|
1-12993 |
|
95-4502084 |
|
(State or other jurisdiction of incorporation) |
|
(Commission |
|
(I.R.S. Employer
|
|
385 East Colorado Boulevard, Suite 299 |
|
|
|
Pasadena, California |
|
91101 |
|
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code: (626) 578-0777
|
N/A |
|
(Former name or former address, if changed since last report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4 (c))
Item 8.01 Other Events
On October 4, 2007, Citigroup Global Markets Inc. and Merrill Lynch, Pierce, Fenner & Smith Incorporated, the underwriters of Alexandria Real Estate Equities, Inc.’s recent follow-on public offering of 2,000,000 shares of common stock, exercised their over-allotment option to purchase an additional 300,000 shares of common stock at a price of $94.15 per share. The closing of the over-allotment option is scheduled for October 10, 2007.
The press release announcing the transaction is attached hereto as Exhibit 99.1 and is filed herewith.
Item 9.01 Financial Statements and Exhibits
|
(d) |
Exhibits |
|
|
|
|
|
|
|
99.1 |
Press Release, dated October 5, 2007 |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
ALEXANDRIA REAL ESTATE EQUITIES, INC. |
|||||
|
|
|
||||
|
|
|
||||
|
Date: |
October 9, 2007 |
By: |
/s/ Dean A. Shigenaga |
|
|
|
|
Dean A. Shigenaga |
|
|||
|
|
Chief Financial Officer |
|
|||
3
Exhibit 99.1
|
For Immediate Release |
|
||
|
|
|
||
|
Contact: |
Joel S. Marcus |
||
|
|
Chief Executive Officer |
||
|
|
Alexandria Real Estate Equities, Inc. |
||
|
|
(626) 578-9693 |
||
ALEXANDRIA REAL ESTATE EQUITIES, INC.
REPORTS EXERCISE OF OVER-ALLOTMENT OPTION BY UNDERWRITERS
PASADENA, CA. — October 5, 2007 - Alexandria Real Estate Equities, Inc. (NYSE:ARE) announced today that the underwriters of its recent follow-on public offering of 2,000,000 shares of common stock have fully exercised their over-allotment option to purchase an additional 300,000 shares of common stock, bringing the total net proceeds to approximately $217 million, after payment of underwriting discounts and commissions. The closing of the over-allotment option is scheduled for October 10, 2007.
Citi and Merrill Lynch, & Co. acted as joint book-running managers of the offering.
Alexandria Real Estate Equities, Inc., Landlord and Developer of Choice to the Life Science Industry®, is a publicly-traded real estate investment trust focused principally on the ownership, operation, management, selective development, redevelopment and acquisition of life science properties. Our properties are designed and improved for lease primarily to institutional (universities and independent not-for-profit institutions), pharmaceutical, biotechnology, medical device, life science product, service, biodefense and translational medicine entities, as well as governmental agencies. We are the largest and leading provider of real estate to the broad and diverse life science industry with an asset base, as of June 30, 2007, that will enable us to grow to approximately 18.8 million square feet consisting of 155 properties approximating 10.8 million square feet, properties undergoing ground-up development approximating 1.2 million square feet, plus an imbedded pipeline for ground-up development approximating 6.8 million square feet.
This press release contains forward-looking statements within the meaning of the federal securities laws. The Company’s actual results might differ materially from those projected in the forward-looking statements. Additional information concerning factors that could cause actual results to differ materially from those in the forward-looking statements is contained in the Company’s Annual Report on Form 10-K and its other periodic reports filed with the Securities and Exchange Commission.
This communication shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
Copies of the prospectus supplement relating to this offering, when available, may be obtained by contacting: Citi, Brooklyn Army Terminal, 140 58th Street, 8th Floor, Brooklyn, New York 11220 (tel: 718-765-6732; fax: 718-765-6734) or Merrill Lynch & Co. (Prospectus Fulfillment), 4 World Financial Center, Prospectus Department, New York, NY 10080.
# # #